CL2016003317A1 - Anticuerpos biespecificos anti-il4-il13 - Google Patents

Anticuerpos biespecificos anti-il4-il13

Info

Publication number
CL2016003317A1
CL2016003317A1 CL2016003317A CL2016003317A CL2016003317A1 CL 2016003317 A1 CL2016003317 A1 CL 2016003317A1 CL 2016003317 A CL2016003317 A CL 2016003317A CL 2016003317 A CL2016003317 A CL 2016003317A CL 2016003317 A1 CL2016003317 A1 CL 2016003317A1
Authority
CL
Chile
Prior art keywords
fragments
double
type
region
antibody
Prior art date
Application number
CL2016003317A
Other languages
English (en)
Inventor
Corrine Esperet
Alexandre Jagarschmiet
Christina Soubrane
Arun Subramaniam
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CL2016003317A1 publication Critical patent/CL2016003317A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>EN EL PRESENTE DOCUMENTO SE DESVELAN DOSIS SEGURAS DE PROTEÍNAS DE UNIÓN DE TIPO ANTICUERPO DE DOBLE REGIÓN V O FRAGMENTOS DE LAS MISMAS, ASÍ COMO MÉTODOS PARA EVALUAR LA UNIÓN DE PROTEÍNAS DE TIPO ANTICUERPO DE DOBLE REGIÓN V O FRAGMENTOS DE LAS MISMAS A SUS DIANAS Y MÉTODOS PARA TRATAR LA FIBROSIS PULMONAR IDIOPÁTICA (FPI) MEDIANTE LA ADMINISTRACIÓN DE DOSIS SEGURAS DE PROTEÍNAS DE UNIÓN DE TIPO ANTICUERPO DE DOBLE REGIÓN V O FRAGMENTOS DE LAS MISMAS. EN ALGUNAS REALIZACIONES, LAS PROTEÍNAS DE UNIÓN DE TIPO ANTICUERPO DE DOBLE REGIÓN V O FRAGMENTOS DE LAS MISMAS SE UNEN TANTO A LA IL-4 COMO A LA IL-13.</p>
CL2016003317A 2014-06-27 2016-12-23 Anticuerpos biespecificos anti-il4-il13 CL2016003317A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462018253P 2014-06-27 2014-06-27
EP14306477 2014-09-24
US201562102097P 2015-01-11 2015-01-11
US201562102555P 2015-01-12 2015-01-12

Publications (1)

Publication Number Publication Date
CL2016003317A1 true CL2016003317A1 (es) 2017-08-11

Family

ID=51663114

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016003317A CL2016003317A1 (es) 2014-06-27 2016-12-23 Anticuerpos biespecificos anti-il4-il13

Country Status (18)

Country Link
US (2) US20170145089A1 (es)
EP (1) EP3160502A2 (es)
JP (1) JP2017530089A (es)
KR (1) KR102558891B1 (es)
CN (1) CN106573975A (es)
AU (1) AU2015278829B2 (es)
BR (1) BR112016030568B8 (es)
CA (1) CA2952902C (es)
CL (1) CL2016003317A1 (es)
CR (1) CR20170022A (es)
EA (1) EA201692495A8 (es)
MX (1) MX390942B (es)
NZ (1) NZ728020A (es)
PH (1) PH12016502569A1 (es)
SG (2) SG11201610594WA (es)
TN (1) TN2016000569A1 (es)
TW (2) TW201628647A (es)
WO (1) WO2015198146A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
TW201628647A (zh) 2014-06-27 2016-08-16 賽諾菲公司 抗－ｉｌ４－ｉｌ１３雙特異性抗體
JP6871948B2 (ja) 2016-04-27 2021-05-19 アッヴィ・インコーポレイテッド 抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法
JP7784898B2 (ja) * 2019-05-24 2025-12-12 サノフイ 全身性硬化症を治療するための方法
US20240117030A1 (en) * 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
ES2070172T3 (es) 1988-04-16 1995-06-01 Celltech Ltd Procedimiento para producir proteinas mediante adn recombinante.
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
BR9606706A (pt) 1995-10-16 1999-04-06 Unilever Nv Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
US6664227B1 (en) * 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US20040023338A1 (en) 2001-10-26 2004-02-05 Heavner George A. IL-4 mutein proteins, antibodies, compositions, methods and uses
CA2464695A1 (en) 2001-10-26 2003-05-01 Centocor, Inc. Il-13 mutein proteins, antibodies, compositions, methods and uses
WO2006042333A2 (en) 2004-10-12 2006-04-20 Xencor, Inc. Prediction and assessment of immunogenicity
EP1824886B1 (en) 2004-11-17 2010-12-22 Amgen Inc. Fully human monoclonal antibodies to il-13
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP2008087194A (ja) 2006-09-29 2008-04-17 Brother Ind Ltd インクジェットプリンタ
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
JP5561689B2 (ja) * 2007-11-28 2014-07-30 独立行政法人理化学研究所 Ｉｌ−１７ｒｂ陽性ｎｋｔ細胞を用いたアレルギー性気道炎症及び／又は気道過敏症の治療薬のスクリーニング方法
JP5439915B2 (ja) 2009-04-09 2014-03-12 ユニマテック株式会社 硬化性含フッ素ポリエーテル組成物
CN102458437B (zh) * 2009-05-05 2015-06-10 诺维莫尼公司 抗il-17f抗体及其使用方法
WO2011052598A1 (ja) 2009-10-26 2011-05-05 国立大学法人大阪大学 画像特徴抽出装置、画像特徴抽出方法、画像認識装置、及び画像認識方法
US20120282276A1 (en) * 2009-11-05 2012-11-08 The Regents Of The University Of Michigan Biomarkers predictive of progression of fibrosis
RU2578468C2 (ru) 2010-12-16 2016-03-27 Дженентек, Инк. Способы диагностики и лечения, связанные с ингибированием th2
TWI719112B (zh) * 2011-03-16 2021-02-21 賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
TWI743461B (zh) * 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
US9574004B2 (en) * 2012-08-21 2017-02-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
PT3889181T (pt) * 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
US20150225479A1 (en) 2014-02-12 2015-08-13 Sanofi Anti-IL-4/Anti-IL-13 Bispecific Antibody/Polyglutamate Formulations
TW201628647A (zh) 2014-06-27 2016-08-16 賽諾菲公司 抗－ｉｌ４－ｉｌ１３雙特異性抗體

Also Published As

Publication number Publication date
US20170145089A1 (en) 2017-05-25
WO2015198146A2 (en) 2015-12-30
AU2015278829A1 (en) 2017-02-02
BR112016030568B8 (pt) 2023-12-05
EP3160502A2 (en) 2017-05-03
WO2015198146A3 (en) 2016-03-31
TW202034954A (zh) 2020-10-01
US20190359703A1 (en) 2019-11-28
TN2016000569A1 (en) 2018-04-04
MX390942B (es) 2025-03-21
SG10201811562YA (en) 2019-01-30
EA201692495A8 (ru) 2017-07-31
MX2017000171A (es) 2017-04-25
CR20170022A (es) 2017-04-04
CA2952902C (en) 2024-02-13
KR102558891B1 (ko) 2023-07-21
TWI745962B (zh) 2021-11-11
BR112016030568B1 (pt) 2023-10-17
US11136388B2 (en) 2021-10-05
JP2017530089A (ja) 2017-10-12
EA201692495A1 (ru) 2017-05-31
KR20170020519A (ko) 2017-02-22
CA2952902A1 (en) 2015-12-30
AU2015278829B2 (en) 2021-03-25
PH12016502569A1 (en) 2017-04-17
SG11201610594WA (en) 2017-01-27
NZ728020A (en) 2022-07-01
TW201628647A (zh) 2016-08-16
CN106573975A (zh) 2017-04-19
BR112016030568A2 (pt) 2018-02-20

Similar Documents

Publication Publication Date Title
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
CY1125979T1 (el) Εκφραση κατασκευασματων και μεθοδων εφαρμογης γενετικης μηχανικης σε μεθυλοτροφους ζυμομυκητες
CY1122701T1 (el) Απελευθερωση πρωτεϊνης με βαση βακτηρια
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
CY1123654T1 (el) Αποδεσμευση πρωτεϊνης me βαση βακτηρια
MX2024001803A (es) Anticuerpos anti-trem2 y metodos para utilizarlos.
PE20170665A1 (es) Anticuerpos anti-tau humanizados
CL2018002687A1 (es) Proteínas de unión y métodos de uso de las mismas
CL2017003023A1 (es) Anticuerpos anti-ctla-4 y métodos de uso de los mismos.
CL2016003317A1 (es) Anticuerpos biespecificos anti-il4-il13
MX2023009421A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
MX2021001098A (es) Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares.
CR20180065A (es) Constructos de anticuerpo biespecíficos que se unen a egfrviii y cd3
UY36370A (es) Polipéptidos fgf-21 modificados y sus usos
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
EA201692539A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
CR20170139A (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
CY1121895T1 (el) Σκευασματα διαλυματος κατασκευασμενων αντισωματων anti-il-23p19
BR112017023131A2 (pt) anticorpos anti- fcrn
MX375524B (es) Anticuerpos anti-axl.
EA201501028A1 (ru) Конструкции митохондриальных белков и их применение
MX389320B (es) Anticuerpos anti-tnfrsf25
CR20170020A (es) Variantes de proteínas de unión al factor h y métodos de uso de estas
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
SV2016005264A (es) Proteínas de fusión tatk-cdkl5, composiciones, formulaciones y uso de estas